Novo Nordisk recently received FDA approval to bring its oral semaglutide formulation, Rybelsus, under the Ozempic brand – aligning oral and injectable semaglutide for type 2 diabetes under a single, highly recognized name…
On February 24, 2026, Novo Nordisk announced it will significantly reduce the wholesale acquisition cost (WAC) of several of its GLP‑1 therapies, effective January 1, 2027…
On February 20, 2026 the U.S. Supreme Court struck down tariffs imposed under the International Emergency Economic Powers Act (IEEPA), holding that Congress did not delegate authority to the President to…
On February 5, 2026, the administration launched TrumpRx, an online platform designed to help cash‑paying patients access prescription drugs at discounted prices. TrumpRx does not dispense medications directly but connects consumers to...
Diabetes technology is evolving faster than ever, and insulin pumps – once used almost exclusively in type 1 diabetes – are now playing a major role across type 2 diabetes (T2D) as well. As automated insulin delivery (AID) systems become more...
